P/E ratio for Integra LifeSciences (IART)
P/E ratio as of April 2023 (TTM): 26.6
According to Integra LifeSciences's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 26.5926. At the end of 2021 the company had a P/E ratio of 33.5.
P/E ratio history for Integra LifeSciences from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 33.5 | -17.93% |
| 2020 | 40.9 | -58.78% |
| 2019 | 99.1 | 59.48% |
| 2018 | 62.2 | 8.54% |
| 2017 | 57.3 | 30.56% |
| 2016 | 43.9 | -103.03% |
| 2015 | < -1000 | -2888.61% |
| 2014 | 52.0 | |
| 2012 | 26.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.7 | -14.68% | 🇺🇸 USA |
 Medtronic MDT | 26.4 | -0.74% | 🇮🇪 Ireland |
 Stryker Corporation SYK | 45.8 | 72.11% | 🇺🇸 USA |
 Teleflex TFX | 32.7 | 22.80% | 🇺🇸 USA |
 Cardinal Health CAH | -16.3 | -161.32% | 🇺🇸 USA |
 Dentsply Sirona
XRAY | -8.85 | -133.29% | 🇺🇸 USA |
 CONMED CNMD | -37.6 | -241.37% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.